![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Nevro Wins FDA Nod for Spinal Cord Stimulation System
Nevro Wins FDA Nod for Spinal Cord Stimulation System
January 10, 2018
Nevro has received FDA approval for its Senza II spinal cord stimulation system.
The system delivers the company’s proprietary HF10 therapy, which provides the spinal cord with electrical pulses to treat pain by interfering with nerve impulses. According to Nevro, it is the “only SCS therapy indicated to provide pain relief without paresthesia.”
The company has been battling in federal court against Boston Scientific over patent infringement allegations involving its SCS therapy.
Upcoming Events
-
21Oct